recombinant human heparan N-sulfatase (SHP610) / Takeda  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
recombinant human heparan N-sulfatase (SHP610) / Takeda
NCT02060526 / 2013-003450-24: Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of rhHNS Administration Via an IDDD in Pediatric Patients With Early Stage MPS IIIA Disease

Completed
2b
21
Europe, US, RoW
Recombinant human heparan N-sulfatase [rhHNS]
Shire
Sanfilippo Syndrome
06/16
06/16
NCT02350816 / 2014-003960-20: An Extension Study to Determine Safety and Efficacy for Pediatric Patients With MPS Type IIIA Disease Who Participated in Study HGT-SAN-093.

Terminated
2
17
Europe, US
HGT-1410, Recombinant Human Heparan N Sulfatase
Shire
Sanfilippo Syndrome, Mucopolysaccharidosis (MPS)
04/19
04/19
NCT01155778 / 2009-015984-15: Safety, Tolerability, Ascending Dose and Dose Frequency Study of rhHNS Via an IDDD in MPS IIIA Patients

Completed
1/2
12
Europe
Recombinant human heparan N-sulfatase (rhHNS)
Shire
Mucopolysaccharidosis (MPS)
09/12
09/12
NCT01299727 / 2010-021348-16: Extension of Study HGT-SAN-055 Evaluating Administration of rhHNS in Patients With Sanfilippo Syndrome Type A (MPS IIIA)

Terminated
1/2
12
Europe
rhHNS-10 mg, Recombinant human heparan N-sulfatase, rhHNS-45 mg, rhHNS-90 mg
Shire
Sanfilippo Syndrome
04/19
04/19

Download Options